Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone678-990-5740
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$46.97 million
Profitability
Miscellaneous
Employees124
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions
What is Alimera Sciences' stock symbol?
Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."
How were Alimera Sciences' earnings last quarter?
Alimera Sciences Inc (NASDAQ:ALIM) announced its earnings results on Monday, July, 29th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.03. The biopharmaceutical company had revenue of $10.86 million for the quarter, compared to analyst estimates of $12.97 million. View Alimera Sciences' Earnings History.
When is Alimera Sciences' next earnings date?
What price target have analysts set for ALIM?
3 analysts have issued 1-year price objectives for Alimera Sciences' stock. Their predictions range from $3.00 to $3.00. On average, they expect Alimera Sciences' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 496.4% from the stock's current price. View Analyst Price Targets for Alimera Sciences.
What is the consensus analysts' recommendation for Alimera Sciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alimera Sciences.
What are Wall Street analysts saying about Alimera Sciences stock?
Here are some recent quotes from research analysts about Alimera Sciences stock:
- 1. According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (8/15/2019)
- 2. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $202M. This includes a discounted cash flow based enterprise value of the firm at $272M, excluding $40M debt and $30M preferred stock. The DCF analysis utilizes a 15% discount rate and a 2% terminal growth rate. Risks include, but are not limited to: (1) failure of ILUVIEN to secure additional regulatory approval; (2) failure of ILUVIEN to achieve commercial success due to market size, penetration rate, and/ or competition; and (3) potential dilution risk." (5/2/2019)
Has Alimera Sciences been receiving favorable news coverage?
Media stories about ALIM stock have been trending negative recently, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alimera Sciences earned a news impact score of -2.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Alimera Sciences.
Are investors shorting Alimera Sciences?
Alimera Sciences saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 157,000 shares, an increase of 81.3% from the June 30th total of 86,600 shares. Based on an average trading volume of 146,000 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.3% of the company's stock are sold short. View Alimera Sciences' Current Options Chain.
Who are some of Alimera Sciences' key competitors?
Some companies that are related to Alimera Sciences include BioXcel Therapeutics (BTAI), XOMA (XOMA), Synlogic (SYBX), Strongbridge Biopharma (SBBP), Lexicon Pharmaceuticals (LXRX), Kala Pharmaceuticals (KALA), IDEAYA Biosciences (IDYA), Paratek Pharmaceuticals (PRTK), Ardelyx (ARDX), Aldeyra Therapeutics (ALDX), Bicycle Therapeutics (BCYC), Mersana Therapeutics (MRSN), GlycoMimetics (GLYC), ProMetic Life Sciences (PFSCF) and Generex Biotechnology (GNBT).
What other stocks do shareholders of Alimera Sciences own?
Who are Alimera Sciences' key executives?
Alimera Sciences' management team includes the folowing people:
- Mr. Charles Daniel Myers, Non-Exec. Chairman & Consultant (Age 65)
- Mr. Richard S. Eiswirth Jr., Pres, CEO & Director (Age 51)
- Dr. Kenneth Green, Consultant (Age 61)
- Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets (Age 55)
- Mr. J. Philip Jones, Chief Financial Officer (Age 55)
Who are Alimera Sciences' major shareholders?
Alimera Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (9.07%), Renaissance Technologies LLC (1.59%), BlackRock Inc. (0.20%) and Tower Research Capital LLC TRC (0.08%). Company insiders that own Alimera Sciences stock include Armistice Capital Master Fund, Armistice Capital, Llc, C Daniel Myers, Philip Ashman and Richard S Eiswirth Jr. View Institutional Ownership Trends for Alimera Sciences.
Which major investors are selling Alimera Sciences stock?
Which major investors are buying Alimera Sciences stock?
ALIM stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Tower Research Capital LLC TRC . Company insiders that have bought Alimera Sciences stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc and Richard S Eiswirth Jr. View Insider Buying and Selling for Alimera Sciences.
How do I buy shares of Alimera Sciences?
Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alimera Sciences' stock price today?
One share of ALIM stock can currently be purchased for approximately $0.5030.
How big of a company is Alimera Sciences?
What is Alimera Sciences' official website?
How can I contact Alimera Sciences?
Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]
MarketBeat Community Rating for Alimera Sciences (NASDAQ ALIM)
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe ALIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
